ANRO Investors Have the Opportunity to Lead the Alto Neuroscience Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alto Neuroscience, Inc. due to allegations of misleading statements regarding the effectiveness of its drug ALTO-100 for treating major depressive disorder (MDD) [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $50,000 in Alto to contact them for discussing legal options [1]. - A federal securities class action has been filed against Alto, with a deadline of September 19, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Alto and its executives violated federal securities laws by making false statements and failing to disclose critical information about ALTO-100's effectiveness [4]. Group 2: Financial Impact and Stock Performance - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial, leading to a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [5]. - Following the announcement, analysts, including Jeffries, reduced their price target for Alto from $33 to $17, citing concerns about the company's biomarker approach to CNS disorders and psychiatry [6].